Healthcare company Surgery Partners (NASDAQ:SGRY) will be reporting results tomorrow morning. Here’s what to look for. Surgery Partners beat analysts’ revenue expectations by 4.3% last quarter, reporting revenues of $864.4 million, up 17.5% year on year. It was a strong quarter for the company, with a solid beat of analysts’ EPS estimates and a narrow beat of analysts’ sales volume estimates. Is Surgery Partners a buy or sell going into earnings? Read our full analysis here, it’s free. This quarter, analysts are expecting Surgery Partners’s revenue to grow 8.7% year on year to $779.6 million, in line with the 7.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.05 per share.Surgery Partners Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Surgery Partners has missed Wall Street’s revenue estimates three times over the last two years. Looking at Surgery Partners’s peers in the outpatient & specialty care segment, some have already reported their Q1 results, giving us a hint as to what we can expect. U.S. Physical Therapy delivered year-on-year revenue growth of 18.1%, beating analysts’ expectations by 4.4%, and Encompass Health reported revenues up 10.6%, topping estimates by 1.7%. U.S. Physical Therapy’s stock price was unchanged after the results, while Encompass Health was up 11.8%. Read our full analysis of U.S. Physical Therapy’s results here and Encompass Health’s results here. Investors in the outpatient & specialty care segment have had steady hands going into earnings, with share prices up 1.5% on average over the last month. Surgery Partners is up 3.9% during the same time and is heading into earnings with an average analyst price target of $31.36 (compared to the current share price of $22.15). Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. View Comments
Surgery Partners (SGRY) Q1 Earnings: What To Expect
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...